Given their efficacy in addressing hyperglycemia, hyperinsulinemia, and excess adipose tissue, GLP-1 based therapies are potentially valuable in preventing and mitigating obesity-related kidney disease. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.